Capstone reaffirms 2026 outlook for $72.1 million revenue, $18.7 million gross profit, $3.8 million adjusted EBITDA

• Capstone Therapeutics reaffirmed full-year 2026 guidance for revenue of $72.1 million.
• Forecast calls for gross profit of $18.7 million.
• Outlook includes about $3.8 million in Stone Business Adjusted EBITDA.
• Guidance follows Q2 organic distribution revenue growth of about 7% year over year amid an estimated 8.5% market decline.
• Current order volumes point to continued strong organic growth in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260916020380) on September 16, 2026, and is solely responsible for the information contained therein.